Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PTN
stocks logo

PTN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
FY2025Q2
0.00
-100%
--
--
0.00
-100%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Palatin Technologies, Inc. (PTN) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 99.18%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+99.18%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Palatin Technologies Inc (PTN.A) is 0.18, compared to its 5-year average forward P/E of -2.21. For a more detailed relative valuation and DCF analysis to assess Palatin Technologies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.21
Current PE
0.18
Overvalued PE
-0.60
Undervalued PE
-3.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.21
Undervalued EV/EBITDA
-2.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
20.95
Current PS
0.30
Overvalued PS
51.68
Undervalued PS
-9.78
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PTN News & Events

Events Timeline

(ET)
2025-05-09
07:33:02
Palatin presents preclinical data on PL9654 and PL9655 at ARVO
select
2025-05-08 (ET)
2025-05-08
16:42:00
Palatin presents results from Phase 3 PL9643 MELODY-1 trial
select
2025-05-08
06:34:26
Palatin announces transition to OTC Pink following NYSE American notice
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-13Newsfilter
Palatin Technologies Completes Increased $18.2 Million Public Offering Following Full Exercise of Underwriters' Over-Allotment Option

  • Trading Resumption: Palatin Technologies' common shares resumed trading on the NYSE under the symbol "PTN" on November 12, 2025, following compliance with listing standards.

  • Public Offering Details: The company closed an underwritten public offering of 2,795,384 shares, raising approximately $18.2 million, which will be used to support its obesity program and for general corporate purposes.

  • Warrants Issued: The offering included Series J and Series K warrants, allowing for the purchase of additional shares, with potential additional proceeds of up to $18.2 million if exercised.

  • Forward-Looking Statements: The press release contains forward-looking statements regarding the company's future performance and the potential exercise of warrants, which are subject to various risks and uncertainties.

[object Object]
Preview
9.0
07-23Benzinga
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study

  • Positive Clinical Trial Results: Abivax SA's stock surged after announcing successful Phase 3 trial results for its drug obefazimod in treating moderately to severely active ulcerative colitis, achieving significant clinical remission rates in both trials.

  • Future Plans and Financials: The company plans to submit regulatory applications based on upcoming maintenance trial results expected in Q2 2026, while also postponing its financial results announcement to September 2025.

[object Object]
Preview
9.5
05-14NASDAQ.COM
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses

  • Financial Performance: Palatin Technologies reported a narrower net loss of $4.81 million in Q1, down from $8.44 million a year ago, attributed to lower operating expenses following the sale of Vyleesi's rights to Cosette Pharmaceuticals.

  • Operational Progress: The company highlighted advancements in its obesity and ocular pipelines, with promising results from Phase 2 and Phase 3 studies, while trading of its stock transitioned from NYSE American to OTC Pink Market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Palatin Technologies Inc (PTN) stock price today?

The current price of PTN is 21.99 USD — it has increased 28.6 % in the last trading day.

arrow icon

What is Palatin Technologies Inc (PTN)'s business?

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The Company's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The Company's PL9588 is being developed as a topical treatment for glaucoma.

arrow icon

What is the price predicton of PTN Stock?

Wall Street analysts forecast PTN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Palatin Technologies Inc (PTN)'s revenue for the last quarter?

Palatin Technologies Inc revenue for the last quarter amounts to 8.85M USD, decreased % YoY.

arrow icon

What is Palatin Technologies Inc (PTN)'s earnings per share (EPS) for the last quarter?

Palatin Technologies Inc. EPS for the last quarter amounts to 4.26 USD, decreased -121.61 % YoY.

arrow icon

What changes have occurred in the market's expectations for Palatin Technologies Inc (PTN)'s fundamentals?

The market is revising No Change the revenue expectations for Palatin Technologies, Inc. (PTN) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 99.18%.
arrow icon

How many employees does Palatin Technologies Inc (PTN). have?

Palatin Technologies Inc (PTN) has 29 emplpoyees as of December 05 2025.

arrow icon

What is Palatin Technologies Inc (PTN) market cap?

Today PTN has the market capitalization of 38.29M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free